AR066904A1 - Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer - Google Patents
Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancerInfo
- Publication number
- AR066904A1 AR066904A1 ARP080102258A ARP080102258A AR066904A1 AR 066904 A1 AR066904 A1 AR 066904A1 AR P080102258 A ARP080102258 A AR P080102258A AR P080102258 A ARP080102258 A AR P080102258A AR 066904 A1 AR066904 A1 AR 066904A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- independently represents
- alkyl
- jnr6c
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 abstract 8
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 nitro, hydroxyl Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 150000001336 alkenes Chemical class 0.000 abstract 2
- 150000001345 alkine derivatives Chemical class 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000027771 Obstructive airways disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000005229 pyrazolopyridines Chemical class 0.000 abstract 1
- 150000005255 pyrrolopyridines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000004862 vasculogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
Abstract
En el presente documento se proporcionan heterociclos sustituidos de las pirrolopiridinas y heterociclos sustituidos de las pirazolopiridinas y las composiciones farmacéuticas que los incluyen. Los heterociclos descritos en el presente documento actuan como moduladores de las quinasas y son de utilidad en el tratamiento de las enfermedades tales como el cáncer, la alergia, el asma, la inflamacion, la enfermedad obstructiva de las vías respiratorias, las enfermedades autoinmunes, la enfermedad metabolica, la infeccion, la enfermedad del SNC, el tumor cerebral, la obesidad, el asma, el trastorno hematologico, la enfermedad neurologica degenerativa, la enfermedad cardiovascular o la enfermedad asociada con angiogénesis, neovascularizacion o vasculogénesis. Reivindicacion 1: Se reivindica un compuesto que se rige por la formula: (1) o un enantiomero, un diastereomero, un racemato o una sal o solvato farmacéuticamente aceptable del mismo, donde: A1 independientemente representa halogeno, ciano, nitro, hidroxilo, alquilo sustituido o insustituido, alqueno sustituido o insustituido, alquino sustituido o insustituido, haloalquilo sustituido o insustituido, cicloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido, heteroarilo sustituido o insustituido, -(CH2)jC(=Z)R3, -(CH2)jOR3, -(CH2)jC(O)R3, -(CH2)jC(O)OR3, -(CH2)jNR4R5, -(CH2)jC(O)NR4R5, -(CH2)jOC(O)NR4R5, -(CH2)JNR6C(O)R3, -(CH2)jNR6C(O)OR3, -(CH2)jNR6C(O)NR4R5, -(CH2)jS(O)mR7, -(CH2)jNR6S(O)2R7 o -(CH2)jS(O)2NR4R5; donde cada j independientemente representa un numero entero comprendido entre 0 y 6 y m independientemente representa un numero entero comprendido entre 0 y 2 y Z es O, S o NR8; siempre que, cuando A1 es -S(O)mR7, m no sea 2 y siempre que A1 no sea -C(O)H, -C(O)NH2, o -C(O)NHMe; X1 independientemente representa -CR2- o -N-; A2 independientemente representa nitro, hidroxilo, haloalquilo, alquilo sustituido o insustituido, alqueno sustituido o insustituido, alquino sustituido o insustituido, cicloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido, aralquilo sustituido o insustituido, heteroarilo sustituido o insustituido, heteroaralquilo sustituido o insustituido, -(CH2)jC(=Z)R3, -(CH2)jOR3, -(CH2)jC(O)R3, -(CH2)jC(O)OR3, -(CH2)jNR4R5, -(CH2)jC(O)NR4R5, -(CH2)jOC(O)NR4R5, -(CH2)jNR6C(O)R3, -(CH2)jNR6C(O)OR3, -(CH2)jNR6C(O)NR4R5, -(CH2)jS(O)mR7, -(Cl-12)jNR6S(O)2R7 o -(CH2)jS(O)2NR4R5; donde cada independientemente representa un numero entero comprendido entre 0 y 6 y m independientemente representa un numero entero comprendido entre 0 y 2; y Z es O, S o NR8; siempre que cuando A1 es metilo, A2 no sea heteroarilo o -C(O)fenilo; R1 independientemente representa halogeno, ciano, nitro, hidroxilo, alquilo sustituido o insustituido, haloalquilo sustituido o insustituido, cicloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido, heteroarilo sustituido o insustituido, -(CH2)jC(=Z)R3, -(CH2)jOR3, -(CH2)jC(O)R3, -(CH2)JC(O)OR3, -(CH2)jNR4R5, -(CH2)jC(O)NR4R5, -(CH2)jOC(O)NR4R5, -(CH2)jNR6C(O)R3, -(CH2)jNR6C(O)OR3, -(CH2)jNR6C(O)NR4R5, -(CH2)jS(O)mR7, -(CH2)jN6RS(O)2R7 o -(CH2)jS(O)2NR4R5; donde cada j independientemente representa un numero entero comprendido entre 0 y 6 y m independientemente representa un numero entero comprendido entre 0 y 2; y Z es O, S o NR8; o R1 y A1 son unidos entre si a los efectos de formar un cicloalquilo sustituido o insustituido de entre 6 y 9 miembros, o un heterocicloalquilo sustituido o insustituido de entre 6 y 12 miembros; R2 independientemente representa hidrogeno, bromo, cloro, fluor, ciano, nitro, alquilo sustituido o insustituido, o haloalquilo sustituido o insustituido; R3 independientemente representa hidrogeno, alquilo sustituido o insustituido, haloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, cicloalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido, o heteroarilo sustituido o insustituido; R4, R5, R6 y R7 cada uno de independientemente representa hidrogeno, alquilo sustituido o insustituido, alquilo-NR9R10 sustituido o insustituido, alquilo-CONR9R10 sustituido o insustituido, heteroalquilo sustituido o insustituido, cicloalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido o heteroarilo sustituido o insustituido, aralquilo sustituido o insustituido, heteroaralquilo sustituido o insustituido, o R4 y R5 son unidos de forma conjunta al nitrogeno al cual se encuentran acoplados, a los fines de formar un heterocicloalquilo sustituido o insustituido de entre 3 y 7 miembros, o un heteroarilo sustituido o insustituido de 5 miembros; R8 independientemente representa hidrogeno, alquilo sustituido o insustituido, haloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, arilo sustituido o insustituido, heteroarilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, o cicloalquilo sustituido o insustituido; R9 y R10 cada uno independientemente representa hidrogeno, alquilo sustituido o insustituido, haloalquilo sustituido o insustituido, heteroalquilo sustituido o insustituido, cicloalquilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido, arilo sustituido o insustituido o heteroarilo sustituido o insustituido, o R9 y R10 son unidos de forma conjunta al nitrogeno al cual se encuentran acoplados, a los fines de formar un heterocicloalquilo sustituido o insustituido de entre 3 y 7 miembros, o un heteroarilo sustituido o insustituido de 5 miembros; donde cualquiera de los grupos enumerados en el caso de R1, R2, R3, R4, R5, R6, R7, R8, R9 y R10 son cada uno opcional e independientemente sustituido con entre 1 y 3 grupos y donde cada uno de estos grupos es seleccionado de manera independiente a partir de halogeno, hidroxilo, amino, aminomonoalquilo, aminodialquilo, ciano, nitro, haloalquilo, alquilo, heteroalquilo, oxo, -O-alquilo y -S-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94058907P | 2007-05-29 | 2007-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066904A1 true AR066904A1 (es) | 2009-09-23 |
Family
ID=40094108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102258A AR066904A1 (es) | 2007-05-29 | 2008-05-29 | Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8158647B2 (es) |
| EP (1) | EP2056822A4 (es) |
| JP (1) | JP2010529035A (es) |
| KR (1) | KR20100041711A (es) |
| CN (1) | CN101778629A (es) |
| AR (1) | AR066904A1 (es) |
| AU (1) | AU2008260120A1 (es) |
| BR (1) | BRPI0813311A2 (es) |
| CA (1) | CA2689161A1 (es) |
| CL (1) | CL2008001540A1 (es) |
| EA (1) | EA200901538A1 (es) |
| MX (1) | MX2009013052A (es) |
| PE (1) | PE20090388A1 (es) |
| TW (1) | TW200908968A (es) |
| UY (1) | UY31113A1 (es) |
| WO (1) | WO2008150914A1 (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| WO2007013896A2 (en) * | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| MY153898A (en) * | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| BRPI0720695A2 (pt) | 2006-12-21 | 2014-02-18 | Plexxikon Inc | Compostos e métodos para modulação de cinase, e indicações para estes |
| PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| JP2010524858A (ja) * | 2007-04-10 | 2010-07-22 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 縮合環複素環キナーゼ調節因子 |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| EP2265270A1 (en) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| JP2012509342A (ja) * | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン |
| EA022924B1 (ru) | 2009-04-03 | 2016-03-31 | Ф.Хоффманн-Ля Рош Аг | ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ |
| PL2440558T3 (pl) | 2009-06-08 | 2015-10-30 | Takeda Pharmaceuticals Co | Związki dihydropirolonaftyrydynony jako inhibitory JAK |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| CA2770320A1 (en) * | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| EP2464232B1 (en) | 2009-08-10 | 2015-10-07 | Samumed, LLC | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2515655B1 (en) | 2009-12-21 | 2015-08-05 | Samumed, LLC | 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof |
| EP2569315A1 (en) | 2010-05-14 | 2013-03-20 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| SI2672967T1 (sl) | 2011-02-07 | 2018-12-31 | Plexxikon Inc. | Spojine in postopki za kinazno modulacijo in indikacije zanjo |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| EP2710003A1 (en) | 2011-05-16 | 2014-03-26 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| IN2014CN02646A (es) | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| CN103214480B (zh) * | 2012-01-19 | 2015-12-16 | 中国科学院广州生物医药与健康研究院 | 吡唑并吡啶炔苯类化合物及其药用组合物和应用 |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| NZ741907A (en) | 2012-05-04 | 2020-02-28 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN105732639A (zh) | 2012-06-29 | 2016-07-06 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| US9908867B2 (en) | 2013-01-08 | 2018-03-06 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof |
| WO2014138212A1 (en) * | 2013-03-06 | 2014-09-12 | Allosteros Therapeutics, Inc. | CaMKII INHIBITORS AND USES THEREOF |
| US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
| JP6782227B2 (ja) | 2014-09-05 | 2020-11-11 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ＣａＭＫＩＩ阻害剤及びその使用 |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| US12241114B2 (en) | 2014-11-04 | 2025-03-04 | Brandeis University | Biophysical platform for drug development based on energy landscape |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| WO2017079765A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | Treatment of osteoarthritis |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| MD3464285T2 (ro) | 2016-06-01 | 2023-01-31 | Biosplice Therapeutics Inc | Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei |
| CN110709082A (zh) | 2016-10-21 | 2020-01-17 | 萨穆梅德有限公司 | 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途 |
| JP7630905B2 (ja) | 2016-11-07 | 2025-02-18 | バイオスプライス セラピューティクス インコーポレイテッド | 単回用量の調整済み注射用製剤 |
| WO2019057660A1 (en) * | 2017-09-25 | 2019-03-28 | Basf Se | INDOLE AND AZAINDOLE COMPOUNDS HAVING 6-CHANNEL SUBSTITUTED ARYL AND HETEROARYL CYCLES AS AGROCHEMICAL FUNGICIDES |
| CN112174951A (zh) * | 2019-07-02 | 2021-01-05 | 深圳美莹基因科技有限公司 | 作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物 |
| CN116143779B (zh) * | 2023-03-10 | 2025-06-13 | 中国药科大学 | 一种造血祖细胞激酶1抑制剂的化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787249A (fr) | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
| US5604091A (en) * | 1984-03-01 | 1997-02-18 | Microgenics Corporation | Methods for protein binding enzyme complementation |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US20030229453A1 (en) | 2002-04-09 | 2003-12-11 | Antonysamy Stephen Suresh | Crystals and structures of PAK4KD kinase PAK4KD |
| WO2004024895A2 (en) * | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| ATE469151T1 (de) * | 2005-05-16 | 2010-06-15 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
-
2008
- 2008-05-28 CL CL2008001540A patent/CL2008001540A1/es unknown
- 2008-05-28 TW TW097119677A patent/TW200908968A/zh unknown
- 2008-05-29 US US12/129,546 patent/US8158647B2/en not_active Expired - Fee Related
- 2008-05-29 JP JP2010510494A patent/JP2010529035A/ja not_active Withdrawn
- 2008-05-29 KR KR1020097027274A patent/KR20100041711A/ko not_active Ceased
- 2008-05-29 WO PCT/US2008/065150 patent/WO2008150914A1/en not_active Ceased
- 2008-05-29 AR ARP080102258A patent/AR066904A1/es unknown
- 2008-05-29 CA CA002689161A patent/CA2689161A1/en not_active Abandoned
- 2008-05-29 UY UY31113A patent/UY31113A1/es unknown
- 2008-05-29 EP EP08780716A patent/EP2056822A4/en not_active Withdrawn
- 2008-05-29 AU AU2008260120A patent/AU2008260120A1/en not_active Abandoned
- 2008-05-29 PE PE2008000917A patent/PE20090388A1/es not_active Application Discontinuation
- 2008-05-29 CN CN200880101167A patent/CN101778629A/zh active Pending
- 2008-05-29 BR BRPI0813311-5A2A patent/BRPI0813311A2/pt not_active IP Right Cessation
- 2008-05-29 MX MX2009013052A patent/MX2009013052A/es not_active Application Discontinuation
- 2008-05-29 EA EA200901538A patent/EA200901538A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8158647B2 (en) | 2012-04-17 |
| PE20090388A1 (es) | 2009-04-30 |
| WO2008150914A1 (en) | 2008-12-11 |
| EP2056822A1 (en) | 2009-05-13 |
| TW200908968A (en) | 2009-03-01 |
| EP2056822A4 (en) | 2009-09-16 |
| CL2008001540A1 (es) | 2009-05-22 |
| US20090005356A1 (en) | 2009-01-01 |
| CA2689161A1 (en) | 2008-12-11 |
| KR20100041711A (ko) | 2010-04-22 |
| UY31113A1 (es) | 2009-01-30 |
| BRPI0813311A2 (pt) | 2014-12-23 |
| AU2008260120A1 (en) | 2008-12-11 |
| JP2010529035A (ja) | 2010-08-26 |
| CN101778629A (zh) | 2010-07-14 |
| EA200901538A1 (ru) | 2010-06-30 |
| MX2009013052A (es) | 2010-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066904A1 (es) | Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer | |
| MX2018000592A (es) | Derivados de etinilo como moduladores del receptor de glutamato metabotropico. | |
| AR074409A1 (es) | Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. | |
| CO6771446A2 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| AR080733A1 (es) | Aril-ciclohexil-tetraazabenzo[e]azulenos, un proceso para su obtencion, una composicion farmaceutica que los contiene y su uso para la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el antagonismo del receptor de v1a | |
| AR063520A1 (es) | Triazoles biciclicos como moduladores de proteina quinasa | |
| AR078495A1 (es) | Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico | |
| AR092628A1 (es) | Piridinonas biciclicas | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| PE20180796A1 (es) | Macrociclos peptidicos contra acinetobacter baumannii | |
| JP2016513130A5 (es) | ||
| BR112020008836A2 (pt) | Moduladores da via de estresse integrada | |
| JP2015520158A5 (es) | ||
| JP2015537008A5 (es) | ||
| JP2015163632A5 (es) | ||
| AR076794A1 (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen | |
| BR112014027190A2 (pt) | pirrolobenzodiazepinas | |
| AR066617A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesis | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| AR082341A1 (es) | Derivados anticancerosos, su preparacion y agentes de seleccion para su aplicacion terapeutica | |
| UY28374A1 (es) | Agentes terapéuticos | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| ECSP11011207A (es) | Composiciones de asfalto mineral que contienen un compuesto de organosilicio catiónico | |
| JP2018533593A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |